Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From NovoStent Corporation
The market for interventional devices designed to treat peripheral artery disease has long taken a backseat to the more high-profile interventional cardiology arena. However, with competitive and economic pressures now driving down prices and profits for coronary stents, manufacturers and investors alike are turning their attention to the still underpenetrated PAD opportunity, where device advancements are expanding the treatable patient population and could drive strong revenue growth in the years ahead.
In Vivo briefly summarizes the technologies of these recently founded companies: Alimera Sciences Ic., CellCentric Ltd., NovoStent Corp., Plantacor Inc., Sadra Medical Inc. and Strata Pharmaceuticals Inc.
- Medical Devices
- Implantable Devices
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.